Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer

Annals of Oncology

Volumn 23, Issue 12, 2012, Pages 3104-3110

  Verschraegen, C F ^a   Czok, S ^b   Muller, C Y ^c   Boyd, L ^b   Lee, S J ^c   Rutledge, T ^c   Blank, S ^b   Pothuri, B ^b   Eberhardt, S ^c   Muggia, F ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Antiangiogenic therapy; Chemotherapy; Ovarian cancer; Platinum resistance

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; GEMCITABINE; PLATINUM; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; APPLICATION SITE REACTION; ARTICLE; ASTHENIA; ATAXIA; BLISTER; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; COGNITIVE DEFECT; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DESQUAMATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSPEPSIA; DYSPHAGIA; DYSPHONIA; DYSPNEA; EPISTAXIS; ESOPHAGEAL EROSION; FATIGUE; GAIT DISORDER; HEART DISEASE; HEART EJECTION FRACTION; HEMIPARESIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTION; KIDNEY DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOENCEPHALOPATHY; MEMORY DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PAIN; PALMAR PLANTAR ERYTHRODERMA; PHARYNGEAL EROSION; PHASE 2 CLINICAL TRIAL; PLAMAR PLANTAR ERYTHRODERMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; SKIN DISEASE; SLURRED SPEECH; THROMBOCYTOPENIA; TOOTH ABSCESS; TOOTH DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; VOMITING; WOUND DEHISCENCE;

EID: 84869799142     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds172     Document Type: Article

References (27)

1. Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep 2001; 3: 156-162.
2. Straubinger RM, Arnold RD, Zhou R et al. Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res 2004; 24: 397-404.
3. Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 2008; 8: 309-316.
4. Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 2004; 31: 5-15.
5. Uziely B, Jeffers S, Isacson R et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777-1785.
6. Safra T, Groshen S, Jeffers S et al. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer 2001; 91: 90-100.
7. Gordon AN, Tonda M, Sun S et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95: 1-8.
8. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 5165-5171.
9. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-5186.
10. Jain KK. Nanotechnology-based drug delivery for cancer. Technol Cancer Res Treat 2005; 4: 407-416.
11. Rustin GJ, Bast RC, Jr, Kelloff GJ et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004; 10: 3919-3926.
12. Rose PG, Tian C, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a gynecologic Oncology Group study. Gynecol Oncol 2010; 117: 324-329.
13. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483.
14. Aghajanian C, Blank SV, Goff BA et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or Fallopian tube cancer. J Clin Oncol 2012; 30: 2039-2045.
15. Larkin C. Is the battle over bevacizumab coverage looming? J Natl Compr Cancer Netw 2011; 9: 261-263.
16. Ocana A, Amir E, Vera F et al. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 2011; 29: 254-256.
17. Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 2007; 107: 118-123.
18. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011; 305: 487-494.
19. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496.
20. Garcia AA, Hirte H, Fleming G et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret hospital phase II consortia. J Clin Oncol 2008; 26: 76-82.
21. Tillmanns TD, Lowe MP, Schwartzberg LS et al. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol 2010; 28 (abstr 5009).
22. D'Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23: 7135-7142.
23. Pignata S, Lauraine EP, du Bois A et al. Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer. Crit Rev Oncol Hematol 2010; 73: 23-30.
24. Kudoh K, Takano M, Kouta H et al. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol 2011; 122: 233-237.
25. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-993.
26. Gordon AN, Granai CO, Rose PG et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093-3100.
27. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28: 3107-3114.